Sooner or later the immune system in most cases suddenly fails to control the virus, and the disease progresses to manifest AIDS (acquired immunodeficiency syndrome). This process is associated with an increase of the virus load and progressive disruption of the lymph node architecture (1) . It would, therefore, be important to know whether the sudden failure of the immune system may result from a defined insult to the immune system that may be a target for therapeutic intervention. A series of recent studies suggests this is indeed the case. In this brief review, we summarize the accumulating body of evidence suggesting that 1) cysteine plays an important role in controlling nitrogen balance and maintaining body cell mass, and 2) a dysregulation of the plasma cystine level and of the cyst(e)ine catabolism is associated with excessive urea production, decrease of plasma glutamine levels, development of skeletal muscle wasting, and immunodeficiencies in several diseases of unrelated etiology.
DEHNITION OF THE "LOW CG SYNDROME"
Diseases and conditions associated with abnormally low plasma cystine and glutamine levels, excessive urea production, an immunological dysfunction Abnormally low plasma cystine and glutamine levels and elevated plasma glutamate levels have been In addition, abnormally low plasma cystine and glufamine levels were observed in patients with sepsis, major injury (9), lung cancer (10), chronic fatigue syndrome (11), Crohn's disease, and ulcerative colitis (12) (see Table 1 1) . These mechanisms are essentially textbook knowledge.
The mechanistic link between cyst(e)ine catabolism and urea production
It has also been known for a long time that protons can be generated in the liver by the catabolism of cyst(e)ine to sulfate (see Fig. ) . The most important function of this regulatory circuit is to ensure that a temporary increase of urea production and a corresponding decrease in plasma amino acid levels trigger a signal in the skeletal muscle tissue to catabolize protein, export cystine, increase thereby the plasma cystine level and cystine catabolism in the liver, and ultimately down-regulate the rate of urea production in the liver. This process thus prevents further loss of amino acids. The adaptive skeletal muscle catabolism typically occurs in the postabsorptive period and may require low insulin levels. Postabsorptive protein catabolism and the corresponding export of amino acids through Natdependent transport systems may also facilitate the Na-dependent uptake of glutamate into skeletal muscle and thereby increase intracellular glutamate and glutathione levels. If glutamate uptake by skeletal muscle tissue is inadequate, plasma glutamate levels increase (see Table 1) and may compromise cystine uptake by the liver through the x, transport system.
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The FASEB Journal DROGE AND HOLM that NAG treatment is capable of increasing not only plasma cystine, but also glutamine, to levels that were even higher than the mean of healthy controls (44). The GD4 T cell numbers did not increase during NAG treatment, but remained essentially stable. The patient illustrated in Fig. 4 had a Note that 1) excessive doses of NAG can also lead to higher than normal plasma cystine and cysteine levels in HIV-infected persons and thereby may impose certain risks (44), and 2) the dose required to raise cystine and glutamine to levels close to the mean of healthy human subjects may vary considerably during the course of the disease (see Fig. 4  and ref 44) . NAG should, therefore, be considered a pharmacological drug rather than a nutritional supplement;
the therapeutic dose of NAG may have to be adjusted to meet individual needs, and should be readjusted at regular intervals. This requirement is analogous to the variable needs of diabetic patients with respect to insulin. The example in Fig. 4 illustrates that the dose of NAG required to maintain close to normal levels of cystine and glutamine was particularly high during a period of massive viremia, longitudinal data of a male HIV-infected healthcare worker who began taking NAG on Dec. 3, 1991, at the age of 50. The dose of NAG was 0.6 g/day at the start, but was subsequently adjusted in an attempt to maintain normal levels of plasma cystine and glutamine with a minimal dose of NAC. The patient did not undergo any antiviral therapy between December 1991 and December 1995. However, after the dose requirements for NAC increased dramatically to 3.6 g/day during 1995 and the virus load was found to be 210,000 copies/ml in December 1995, the patient decided to use a complementary antiviral therapy (DDI plus a hydroxyurea derivative). During this treatment, the plasma cystine and glutamine levels increased spontaneously and the dose of NAC was decreased accordingly. In November 1996, the patient had a virus load of 10,000 copies/ml and from thereon maintained stable cystine and glutamine levels with doses of NAC between 600 and 1200 mg/day. The figure also shows that the patient acquired essentially normal plasma glutamate levels under NAG treatment. After 5 years of treatment, he had approximately the same CD4 and CD8 counts and the same body weight and body cell mass as before treatment. The main conclusion from this anecdotal case is that the dose requirement for NAG varies considerably during the course of infection and has to be adjusted according to individual needs. 
